Skye Bioscience (FRA:09R) Total Payout Ratio: 0.00 (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:09R Skye Bioscience Inc FRA:09R
20 GF Score
Price €0.41
! 1 Warning Sign
View Full Analysis

What is Skye Bioscience Total Payout Ratio?

Skye Bioscience FRA:09R +3.00% 20 Total Payout Ratio is 0.00 as of Aug. 12, 2026. GuruFocus rates FRA:09R with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Skye Bioscience's current Total Payout Ratio is 0.00.

Skye Bioscience Total Payout Ratio Related Terms

Skye Bioscience Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Skye Bioscience's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skye Bioscience Total Payout Ratio Chart

Skye Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.00 0.31 3.15 0.00

Skye Bioscience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:09R vs ATOS, JSPR, TVRD: Total Payout Ratio Comparison

For the Biotechnology subindustry, Skye Bioscience's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skye Bioscience Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Total Payout Ratio falls into.


FRA:09R
20GF Score
Skye Bioscience Inc FRA:09R
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Skye Bioscience Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Skye Bioscience's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -47.76
=0.00

Skye Bioscience's Total Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -10.82
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
Skye Bioscience (FRA:09R) has a Total Payout Ratio of 0.00 as of Aug. 12, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Skye Bioscience and its competitors.
Is Skye Bioscience's Total Payout Ratio too high?
Skye Bioscience's current Total Payout Ratio is 0.00. Overall, Skye Bioscience has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Skye Bioscience's Total Payout Ratio compare to ATOS and JSPR?
Skye Bioscience's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Skye Bioscience and its competitors. Skye Bioscience's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Skye Bioscience stock overvalued right now?
Skye Bioscience (FRA:09R) has a current Total Payout Ratio of 0.00. The current Total Payout Ratio is 0.00. Skye Bioscience's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Skye Bioscience (FRA:09R), the current Total Payout Ratio is 0.00 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Skye Bioscience Business Description

Other Exchanges SKYE:USA
Address 11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
20GF Score

Get the complete analysis for FRA:09R

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price